New Bladder Cancer Molecular Classification Predicts Response to Common Immunotherapy
The new subtypes could help clinicians pick alternative therapies for patients unlikely to respond to Bacillus Calmette-Guérin treatment.
ObjectiveHealth, Urology of St. Louis Launch Research Partnership
A joint clinical research center based in St. Louis will provide access to investigative therapies and diagnostic tools to improve outcomes in urologic diseases.
GeneCentric Begins Study to Validate RNA Gene Signature Test in Bladder Cancer
GeneCentric investigators will assess the ability of the FGFR predictive response signature to identify bladder cancer patients who may benefit from targeted therapy.
Culmination Bio, Cofactor Genomics Team up on Study to Advance Immunotherapy Response Test
Culmination will give Cofactor access to over 4.5 million biological samples to advance the firm's assay to predict immunotherapy response in 11 cancer types.
Nucleix Bladder EpiCheck Cancer Liquid Biopsy Test Gets FDA 510(k) Clearance
The DNA methylation-based urine PCR test is cleared for monitoring patients diagnosed with non-muscle invasive bladder cancer for recurrence.